Search Results
May 21, 2026, 17:00 ET Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
RetevmoRetevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. RET-driver alterations are predominantly mutually
More news about: Eli Lilly and Company
May 21, 2026, 16:30 ET Cohen & Steers Appoints Amit Muni as Chief Financial Officer
NEW YORK, May 21, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that Amit Muni has been appointed as Executive Vice President and Chief Financial Officer, effective June 8, 2026. Mr. Muni will lead
More news about: Cohen & Steers, Inc.
May 21, 2026, 05:31 ET Charcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsight
Reductase Inhibitor (ARI) under development for several rare disorders, including CMT-SORD. It is designed to penetrate the central nervous system (CNS) and offers a more targeted mechanism of action than earlier ARIs, minimizing off-target effects. The therapy has been granted Orphan Medicinal Product
More news about: DelveInsight Business Research, LLP
May 20, 2026, 21:00 ET Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
NEW YORK, May 21, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund for
More news about: Cohen & Steers, Inc.
May 20, 2026, 21:00 ET Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
NEW YORK, May 20, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund for
More news about: Cohen & Steers, Inc.
May 20, 2026, 08:49 ET Vertical Pharmaceuticals Partners with Medfinder to Help Patients Find Relexxii® During Ongoing ADHD Medication Shortages
treatments. INDICATION & IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING INDICATION RELEXXII is a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults (up to the age of 65 years) and pediatric patients
More news about: Alora Pharmaceuticals, LLC
May 20, 2026, 08:08 ET Eisai Deepens Body of Clinical Evidence for LENVIMA (Lenvatinib) Across Established Indications at ASCO 2026
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
May 19, 2026, 18:00 ET LG CNS Expands North American AX Business, Supporting Smart Factory Transformation for SMEs
servicesSEOUL, South Korea, May 19, 2026 /PRNewswire/ -- LG CNS is accelerating its expansion into the North American manufacturing AX market with advanced AI-powered smart factory solutions.
More news about: LG CNS
May 19, 2026, 14:00 ET Myosin Therapeutics Initiates Phase 1/2 STAR-GBM Trial of MT-125 Targeting Non-muscle Myosin II in Newly Diagnosed Glioblastoma
TherapeuticsMyosin Therapeutics is a biotechnology company based in Jupiter, Florida, developing first-in-class therapies for oncology and CNS disorders by targeting molecular nanomotor proteins. The company's lead program, MT-125, is designed to disrupt tumor cell mechanics across multiple
More news about: Myosin Therapeutics Inc.
May 19, 2026, 09:00 ET Signant Health Engages CNS Community at ASCP 2026 Following Acquisition of Ametris
objective, and high-fidelity data collection, particularly important in central nervous system (CNS) and other complex therapeutic areas."ASCP is a key forum for advancing innovation in psychopharmacology and CNS research," said Dawie Wessels, Signant's chief medical officer. "Our engagement this year
More news about: Signant Health
May 19, 2026, 08:00 ET 28bio Launches CNS-3D Inflammatory Organoids to Predict Anti-inflammatory Therapeutic Efficacy
said Stuart Gibb, Head of Business Development at 28bio. "CNS-3D Inflammatory Organoids are available as assay-ready products in 24-, 48-, 96-, and 384-replicate formats or services beginning in Q3'26."Following the recent launch of CNS-3D Myelinated Organoids, this announcement marks another
More news about: 28bio
May 19, 2026, 08:00 ET Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
stabilization of symptoms in hours and no intensive monitoring requirement. LPCN 1154 has demonstrated clinically meaningful improved tolerability including low CNS depressant side effects, without the risks of disassociation or hallucination of psychedelics, thus potentially enabling a safe, at-home intervention,
More news about: Lipocine Inc.
May 18, 2026, 13:03 ET Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing
rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.For more information, visit
More news about: LifeSpan Vision Ventures
May 18, 2026, 13:03 ET Lifespan Vision Ventures Leads Violet Therapeutics' $4.75M Seed Extension Financing
rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.For more information, visit
More news about: LifeSpan Vision Ventures
May 18, 2026, 08:40 ET Connected Nation releases 2025 national impact report, launches interactive digital empowerment dashboard
dashboard reflect the reach of our digital empowerment work and the impact it has across the country.Together, the report and dashboard highlight CN's growing impact in expanding access to broadband, building digital skills, and creating pathways to economic opportunity. In 2025 alone, CN trained more
More news about: CONNECTED NATION, INC.
May 18, 2026, 08:05 ET FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization
Intas Pharmaceuticals, Ltd. ("Intas Pharmaceuticals"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved IMMGOLIS™ (golimumab-sldi), a biosimilar to Simponi® (golimumab),
More news about: Accord BioPharma
May 18, 2026, 08:00 ET Bio-Thera Solutions' Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States
Intas Pharmaceuticals, Ltd. ("Intas"), focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced Accord BioPharma received marketing authorization in the United States of America for IMMGOLIS (formerly known as BAT2506),
More news about: Bio-Thera Solutions, Ltd
May 15, 2026, 08:20 ET Pulmatrix Announces First Quarter 2026 Financial Results
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.
May 14, 2026, 16:33 ET Multiple Sclerosis Association of America Appoints New President & CEO
SclerosisMultiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
May 14, 2026, 11:40 ET Introducing The Nexus Forum: A New Global Biopharma Partnership Summit to Accelerate China-Global Strategic Collaboration
international healthcare conferences and investment forums. The platform will initially focus on oncology, autoimmune disease, and later expand into CNS, metabolic disorders, next-generation biologics, cell therapy, and AI-enabled drug discovery."The Nexus Forum was created to become far more than
More news about: The Nexus Prelude
May 14, 2026, 10:02 ET EMA Wellness and Mira Analytics Enter into Exclusive Partnership to use Proprietary AI to Validate Endpoints in Clinical Trials
outcomes in CNS clinical trials through contemporary, validated technology. The EMAW platform is being used in more than 25 countries and by over 250 sites.About Mira Analytics Mira Analytics builds AI models that bring precision and consistency to clinical measurement in CNS trials.
More news about: EMA Wellness
May 14, 2026, 08:56 ET China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable
More news about: China Pharma Holdings, Inc.
May 14, 2026, 07:00 ET Signant Health Acquires Ametris to Create an End-to-End eCOA and Digital Outcome Measures Platform
world-class technologies into Signant, we provide sponsors with complementary perspectives on patient functioning over time. This is particularly valuable in CNS and other complex therapeutic areas where sponsors need multiple lines of evidence to demonstrate meaningful benefit. Together, we're giving sponsors
More news about: Signant Health
May 13, 2026, 16:05 ET Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases. About IBTROZIIBTROZI is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough
More news about: Nuvation Bio Inc.
May 13, 2026, 09:15 ET AndzonBio2, the ALBORADA Drug Discovery Institute at the University of Cambridge and Cambridge Enterprise Announce a Collaboration to Develop First-in-Class Therapeutics for Neuroinflammation
a central driver of multiple neurodegenerative and neurological conditions such as Parkinson's, Alzheimer's, Amyotropic Lateral Sclerosis and other CNS disorders.
More news about: AndzonBio2